Is ILKAY a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Eneabba refinery commissioning and the shift from capex to revenue, with revenue (fy2025, year to 31 dec) at ~A$1.02B group, of which ~A$976M was mineral sands (about US$0.70B converted at roughly US$0.69 per A$1). The bear case rests on iluka's mineral sands earnings are cyclical and price-taking, and the 2025 result showed how quickly a soft pigment market flows through to revenue, impairments and the dividend. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Iluka's mineral sands earnings are cyclical and price-taking, and the 2025 result showed how quickly a soft pigment market flows through to revenue, impairments and the dividend. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

Eneabba refinery commissioning and the shift from capex to revenue. The Eneabba refinery is the single largest swing factor in the story, moving Iluka from mining concentrate to selling separated magnet oxides.

Iluka's mineral sands earnings are cyclical and price-taking, and the 2025 result showed how quickly a soft pigment market flows through to revenue, impairments and the dividend. The Eneabba refinery is a first-of-its-kind plant in Australia, so commissioning delays, ramp-up difficulties and cost overruns are live possibilities, and the timeline has already moved from 2026 to 2027. Rare earth prices are influenced by Chinese state-linked producers and by policy decisions in several countries, which makes the refinery's realised margins hard to forecast even with take-or-pay contracts in place. Group net debt was around A$1.06B at December 2025 including the drawn government loan, so the balance sheet carries project risk while the operating business runs below capacity. For a US holder there is an additional layer that has nothing to do with the mine: the ADR is unsponsored and thinly traded, so wide spreads, gaps against the ASX close, depositary fees and Australian dollar movements can all separate the receipt's return from the underlying share's return.

Iluka Resources Limited is one of the world's largest producers of zircon and a major supplier of high grade titanium dioxide feedstocks, principally rutile and synthetic rutile.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Eneabba refinery commissioning and the shift from capex to revenue) stalling in the reported numbers rather than in the narrative, the risk above (iluka's mineral sands earnings are cyclical and price-taking, and the 2025 result showed how quickly a soft pigment market flows through to revenue, impairments and the dividend) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

One ILKAY depositary receipt represents five Iluka Resources ordinary shares listed on the ASX under the ticker ILU. That ratio is why the ADR quote (recently around US$23) looks so different from the ASX quote (recently around A$6.78): five ordinary shares at roughly A$6.78 convert to about US$23 at an exchange rate near US$0.69 per Australian dollar. If you want to sanity check the ADR price at any time, multiply the ASX price by five, then multiply by the AUD/USD rate. Persistent gaps between that arithmetic result and the traded ADR price are a feature of thin over-the-counter trading, not a sign that the two lines represent different economics.

Iluka does not run a sponsored ADR programme. The receipts exist because depositary banks created them against ordinary shares held in custody, which is what unsponsored means: the company itself is not a party to the arrangement, did not list on a US exchange, and does not file US-style reports for it. That is why the line sits on the OTC market rather than on NYSE or Nasdaq, and it is also why there is no company investor relations page dedicated to the ADR. Practically, unsponsored receipts tend to have wider bid-ask spreads, lower volume, no exchange-listed options in most cases, and depositary service fees that can be deducted from dividends or charged periodically. Some brokers also restrict or surcharge OTC foreign receipts, so the mechanics are worth checking before assuming the line behaves like a US-listed stock.

Iluka pays fully franked dividends, which is the Australian dividend imputation system: the company has already paid Australian corporate tax on the profits, and the credit for that tax is attached to the dividend. Under Australian rules a fully franked dividend paid to a non-resident is generally exempt from Australian dividend withholding tax, so a US holder typically does not lose the 15% treaty rate on the franked portion, though any unfranked component can be subject to withholding. The franking credit itself, however, is generally of no use to a US taxpayer: non-residents cannot claim a refund of franking credits under Australian law, and the US tax system does not treat the underlying Australian company tax as paid by the shareholder, so there is normally no US foreign tax credit for it either. The practical result is that an Australian resident and a US ADR holder can receive very different after-tax value from the same dividend. This is general information about how the system works and not tax advice, so a tax professional is the right place to confirm your own position.